Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in ...

Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

Carolyn Adelsten woke up feeling like something was in her eye and it wouldn't come out. She visited an eye specialist, got a diagnosis of mild dry eye disease and was told to ...

I’m writing in response to Kay Johnson’s Jan. 10 article, “Writing through pain.” While her statement is correct that a Minnesota chapter of the Lupus Foundation of America does not ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

July 10, 2024 — Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect ...

Thyroid problems are rapidly surging in pregnant women and are a major concern as they can affect the health of both the mother and the baby. The thyroid gland produces hormones that are responsible ...

A recent study finds that genetically predicted rheumatoid arthritis is causally associated with prostate cancer.

Your gut microbiome can trigger an immune response, leading to chronic systemic inflammation and lupus. Here are some tips to ...